Spinocerebellar ataxia type 29

Spinocerebellar ataxia type 29 (SCA29) is a rare autosomal dominant neurological disorder characterized by nonprogressive or very slowly progressive cerebellar ataxia with onset in infancy or early childhood. SCA29 is caused by heterozygous mutations in the ITPR1 gene (inositol 1,4,5-trisphosphate receptor type 1) on chromosome 3p26. This gene encodes a calcium channel that plays a critical role in cerebellar Purkinje cell function. SCA29 is sometimes considered allelic with SCA15/SCA16, which are caused by deletions in the same gene but typically present later in life with a more progressive course. SCA29 has also been referred to as congenital nonprogressive spinocerebellar ataxia. The disease primarily affects the cerebellum and its connections, leading to impaired coordination and balance. Key clinical features include early-onset gait and limb ataxia, delayed motor milestones, hypotonia, dysarthria (slurred speech), and intention tremor. Cognitive impairment of variable severity, including mild intellectual disability or learning difficulties, has been reported in some patients. Brain MRI may show cerebellar atrophy, particularly of the vermis, though imaging can also appear normal in some cases. Nystagmus and other oculomotor abnormalities may also be present. There is currently no cure or disease-modifying treatment for SCA29. Management is supportive and symptomatic, focusing on physical therapy and occupational therapy to optimize motor function, speech therapy for dysarthria, and educational support for cognitive difficulties. The prognosis is generally more favorable than many other spinocerebellar ataxias because the condition tends to be nonprogressive or only slowly progressive, and affected individuals often achieve independent ambulation, though with persistent coordination difficulties.

Common questions about Spinocerebellar ataxia type 29